These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 37014050)
41. Development of nano-carriers for Askarizadeh A; Badiee A; Khamesipour A Expert Opin Drug Deliv; 2020 Feb; 17(2):167-187. PubMed ID: 31914821 [No Abstract] [Full Text] [Related]
42. Vaccine-like nanomedicine for cancer immunotherapy. Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241 [TBL] [Abstract][Full Text] [Related]
43. Polyethylenimine Hybrid Thin-Shell Hollow Mesoporous Silica Nanoparticles as Vaccine Self-Adjuvants for Cancer Immunotherapy. Liu Q; Zhou Y; Li M; Zhao L; Ren J; Li D; Tan Z; Wang K; Li H; Hussain M; Zhang L; Shen G; Zhu J; Tao J ACS Appl Mater Interfaces; 2019 Dec; 11(51):47798-47809. PubMed ID: 31773941 [TBL] [Abstract][Full Text] [Related]
44. Polymeric nanoparticle-based nanovaccines for cancer immunotherapy. Zhang Y; Chen J; Shi L; Ma F Mater Horiz; 2023 Feb; 10(2):361-392. PubMed ID: 36541078 [TBL] [Abstract][Full Text] [Related]
45. Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. Chatzikleanthous D; O'Hagan DT; Adamo R Mol Pharm; 2021 Aug; 18(8):2867-2888. PubMed ID: 34264684 [TBL] [Abstract][Full Text] [Related]
46. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Tefit JN; Serra V Expert Rev Vaccines; 2011 Aug; 10(8):1207-20. PubMed ID: 21854313 [TBL] [Abstract][Full Text] [Related]
47. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. Dillon PM; Petroni GR; Smolkin ME; Brenin DR; Chianese-Bullock KA; Smith KT; Olson WC; Fanous IS; Nail CJ; Brenin CM; Hall EH; Slingluff CL J Immunother Cancer; 2017 Nov; 5(1):92. PubMed ID: 29157306 [TBL] [Abstract][Full Text] [Related]
48. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391 [TBL] [Abstract][Full Text] [Related]
49. Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. Kaczmarek M; Poznańska J; Fechner F; Michalska N; Paszkowska S; Napierała A; Mackiewicz A Cells; 2023 Aug; 12(17):. PubMed ID: 37681891 [TBL] [Abstract][Full Text] [Related]
53. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? Ho NI; Huis In 't Veld LGM; Raaijmakers TK; Adema GJ Front Immunol; 2018; 9():2874. PubMed ID: 30619259 [TBL] [Abstract][Full Text] [Related]
54. Applications of chemokines as adjuvants for vaccine immunotherapy. Mohan T; Zhu W; Wang Y; Wang BZ Immunobiology; 2018; 223(6-7):477-485. PubMed ID: 29246401 [TBL] [Abstract][Full Text] [Related]
55. Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction. Zhao Z; Harris B; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C Biomaterials; 2018 Feb; 155():165-175. PubMed ID: 29179132 [TBL] [Abstract][Full Text] [Related]
56. Polysaccharides derived from Chinese medicinal herbs: A promising choice of vaccine adjuvants. Wan X; Yin Y; Zhou C; Hou L; Cui Q; Zhang X; Cai X; Wang Y; Wang L; Tian J Carbohydr Polym; 2022 Jan; 276():118739. PubMed ID: 34823775 [TBL] [Abstract][Full Text] [Related]